| scholarly article | Q13442814 |
| P2093 | author name string | Caroline Le Jeune | |
| Xavier Thomas | |||
| P2860 | cites work | Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia | Q72382840 |
| Comparative pharmacokinetic studies of three asparaginase preparations | Q72888578 | ||
| Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia | Q73053025 | ||
| Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials | Q73063060 | ||
| Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia | Q73164293 | ||
| L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure | Q73668742 | ||
| Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia | Q73818814 | ||
| TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI | Q76897401 | ||
| L-Asparaginase inhibits the rapamycin-targeted signaling pathway | Q77994855 | ||
| The requirement for L-asparagine of mouse leukemia cells L5178Y in culture | Q78866063 | ||
| Histopathological Features of L-Asparaginase-Induced Liver Disease | Q79108821 | ||
| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms | Q79734535 | ||
| Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase | Q80306473 | ||
| Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands | Q80860639 | ||
| Pegasparaginase: where do we stand? | Q82871158 | ||
| Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials | Q84975509 | ||
| Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells | Q27851400 | ||
| The hallmarks of aging | Q28131641 | ||
| Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum | Q28208952 | ||
| Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries | Q28362566 | ||
| Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells | Q28367265 | ||
| Use of ?-asparaginase in childhood ALL | Q29041017 | ||
| A gene expression database for the molecular pharmacology of cancer | Q29619242 | ||
| Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel | Q31038779 | ||
| A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors | Q32061587 | ||
| Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. | Q32061751 | ||
| Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study | Q33447912 | ||
| Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia | Q33680270 | ||
| The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. | Q33718822 | ||
| Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. | Q34011217 | ||
| Drug-induced erythrocyte membrane internalization | Q34072077 | ||
| Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia | Q34131844 | ||
| l-Asparaginase resistance in human leukemia—Asparagine synthetase | Q34223773 | ||
| Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial | Q34300854 | ||
| A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. | Q34373138 | ||
| L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase | Q34400424 | ||
| Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. | Q34455093 | ||
| Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial | Q34522156 | ||
| Age and acute myeloid leukemia | Q34564663 | ||
| Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study | Q34646298 | ||
| Acute lymphoblastic leukemia in the elderly | Q34976235 | ||
| Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia | Q35616085 | ||
| Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase | Q35677647 | ||
| Drug, enzyme and peptide delivery using erythrocytes as carriers | Q35687802 | ||
| High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly | Q35988637 | ||
| Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group | Q36058255 | ||
| Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future | Q36097233 | ||
| L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer | Q36157405 | ||
| Escherichia coli L-asparaginase. Catalytic activity and subunit nature | Q47757113 | ||
| Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen | Q47812693 | ||
| Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia | Q48721339 | ||
| l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. | Q50545214 | ||
| Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. | Q53553679 | ||
| Biochemical and pharmacological studies with asparaginase in man | Q53914602 | ||
| Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. | Q54101707 | ||
| L-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism. | Q54229266 | ||
| Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. | Q54541843 | ||
| Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. | Q54583586 | ||
| Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia | Q56999328 | ||
| Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia | Q62607772 | ||
| Asparaginase entrapped in red blood cells: action and survival | Q67524547 | ||
| The effects of immunization to L-asparaginase on antitumor and enzymatic activity | Q69240677 | ||
| Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase | Q69368205 | ||
| High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA | Q69484184 | ||
| Clinical pharmacology of polyethylene glycol-L-asparaginase | Q69881717 | ||
| Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia | Q70332982 | ||
| L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia | Q70919560 | ||
| Inhibition of leukemias in man by L-asparaginase | Q70927808 | ||
| Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells | Q71256026 | ||
| Evaluation of L-asparagine metabolism in animals and man | Q71742793 | ||
| L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase | Q71751976 | ||
| Treatment of acute lymphoblastic leukemia | Q36366185 | ||
| International seminar on the red blood cells as vehicles for drugs. | Q36382149 | ||
| Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols | Q36392995 | ||
| Survival for older patients with acute myeloid leukemia: a population-based study | Q36662052 | ||
| Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut | Q36678136 | ||
| Applications of carrier erythrocytes in delivery of biopharmaceuticals | Q36725488 | ||
| PEG-asparaginase | Q36909298 | ||
| Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia | Q36918761 | ||
| L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). | Q37371369 | ||
| Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia | Q37734163 | ||
| The identification of neutral amino acid transport systems | Q37904936 | ||
| Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel | Q37914185 | ||
| Asparaginase-associated pancreatitis in children | Q38036389 | ||
| Erwinia asparaginase in pediatric acute lymphoblastic leukemia | Q38040418 | ||
| Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia | Q38046895 | ||
| A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study | Q38409519 | ||
| Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. | Q38879052 | ||
| Pancreatic tumor sensitivity to plasma L-asparagine starvation | Q39362734 | ||
| Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. | Q39905868 | ||
| A new mechanism of leukemia drug resistance? | Q40111510 | ||
| Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines. | Q40464790 | ||
| Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group | Q40882193 | ||
| Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial | Q40917733 | ||
| Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines | Q41515973 | ||
| Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia | Q42943448 | ||
| L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease | Q43656520 | ||
| Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration | Q43774280 | ||
| A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study | Q43904527 | ||
| Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase | Q43973228 | ||
| The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison | Q44229660 | ||
| Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL | Q44605536 | ||
| In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia | Q44665397 | ||
| L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment | Q44666932 | ||
| Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia | Q44824850 | ||
| Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). | Q44903947 | ||
| Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). | Q46069016 | ||
| Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. | Q46095251 | ||
| Hydrogel-magnetic nanoparticles with immobilized L-asparaginase for biomedical applications. | Q46153114 | ||
| Antagonism of purified asparaginase from guinea pig serum toward lymphoma | Q46170945 | ||
| Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. | Q46174384 | ||
| Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia | Q46360551 | ||
| Treatment of lymphosarcoma in the dog with L-asparaginase | Q46439798 | ||
| L-asparagine and leukemia | Q46738473 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 11-25 | |
| P577 | publication date | 2016-05-05 | |
| P1433 | published in | International journal of hematologic oncology | Q27724632 |
| P1476 | title | Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. | |
| P478 | volume | 5 |
| Q90524204 | Erythrocytes as Carriers: From Drug Delivery to Biosensors | cites work | P2860 |
Search more.